A possible association between the CCK-AR gene and persistent auditory hallucinations in schizophrenia

European Psychiatry

Volumn 19, Issue 6, 2004, Pages 349-353

  Sanjuan, J ^a   Toirac, I ^b   Gonzalez J C ^a   Leal, C ^a   Molto M D ^b   Najera C ^b   De Frutos, R ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Association analysis; Auditory hallucinations; Cholecystokinin A receptor; Persistent hallucinations; Schizophrenia

Indexed keywords

CHOLECYSTOKININ A RECEPTOR;

ADULT; ARTICLE; AUDITORY HALLUCINATION; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PATIENT CODING; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

ADULT; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENOTYPE; HALLUCINATIONS; HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; MALE; PERIODICITY; POLYMORPHISM, GENETIC; QUESTIONNAIRES; RECEPTOR, CHOLECYSTOKININ A; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 4444261905     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2004.06.015     Document Type: Article

References (37)

1. Andreasen N.C., Flaum M. Schizophrenia: the characteristic symptoms. Schizophr Bull. 17:1991;27-49
2. Bachus S.E., Hyde T.M., Herman M.M., Egan M.F., Kleinman J.E. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. J Psychiatr Res. 31:1997;233-256
3. Beinfeld M.C. An introduction to neuronal cholecystokinin. Peptides. 8:2001;1197-2000
4. Cheung P., Schweitzer I., Crowley K., Tuckwell V. Violence in schizophrenia: role of hallucinations and delusions. Schizophr Res. 26:1997;81-90
5. Conley R.R., Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 23:1997;663-674
6. David A.S. Auditory hallucinations: phenomenology, neuropsychology and neuroimaging update. Acta Psychiatr Scand. 395:1999;95-104
7. Falloon I.R., Talbot R.E. Persistent auditory hallucinations: coping mechanisms and implications for management. Psychol Med. 11:1981;329-339
8. Farmery S.M., Owen F., Poulter M., Crow T.J. Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. Life Sci. 36:1985;473-477
9. Feifel D., Reza T., Robeck S. Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis. Neuropsychopharmacology. 20:1999;141-149
10. Ferrier I.N., Crow T.J., Farmery S.M., Roberts G.W., Owen F., Adrian T.E., Bloom S.R. Reduced cholecystokinin levels in the limbic lobe in schizophrenia. A marker for pathology underlying the defect state? Ann NY Acad Sci. 448:1985;4995-5011
11. Funakoshi A., Miyasaka K., Matsumoto H., Yamamori S., Takigucji S., Kataoka Y., Matsusue K., Kono A., Shimokata H. Gene structure of human cholecystokinin (CCK) type A receptor: body fat content is related to CCK type-A receptor gene promoter polymorphism. FEBS Lett. 466:2000;264-266
12. Garver D.L., Holcomb J.A., Christensen J.D. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. J Clin Psychiatry. 61:2000;964-972
13. Haddock G., McCarron J., Tarrier N., Faragher E.B. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med. 29:1999;879-888
14. Inoue H., Iannoti C.A., Welling C.M., Veile R., Donis-Keller H., Permutt M.A. Human cholecystokinin type A receptor gene: cytogenetic localization, physical mapping, and identification of two missense variants in patients with obesity and non-insulin-dependent diabetes mellitus (NIDDM). Genomics. 42:1997;331-335
15. Ise K., Akiyoshi J., Horinuchi Y., Tsutsumi T., Isogawa K., Nagayama H. Association between the CCK-A receptor gene and panic disorder. Am J Med Genet. 118:2003;29-31
16. Jenner J.A., Van de Willige G., Wiersma D. Effectiveness of cognitive therapy with coping training for persistent auditory hallucinations: a retrospective study of attenders of a psychiatric out-patient department. Acta Psychiatr Scand. 98:1998;384-389
17. Kane J.M., Honigfeld G., Singer J., Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull. 24:1988;62-67
18. Kennedy J.L., Bradwejn J., Koszycki D., King N., Crowe R., Vincent J., et al. Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry. 4:1999;284-285
19. Kerwin R., Robinson P., Stephenson J. Distribution of CCK binding sites in the human hippocampal formation and their alteration in schizophrenia: a post-mortem autoradiographic study. Psychol Med. 22:1992;37-43
20. Lawrie S.M., Buechel C., Whalley H.C., Frith C.D., Friston K.J., Johnstone E.C. Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry. 51:2002;1008-1111
21. Lesch K.P. Hallucinations: psychopathology meets functional genomics. Mol Psychiatry. 3:1998;278-281
22. Morrison A.P., Wells A., Nothard S. Cognitive factors in predisposition to auditory and visual hallucinations. Br J Clin Psychol. 39:2000;67-78
23. Nair N.P., Lal S., Thavundayil J.X., Wood P.L., Etienne P., Guyda H. CCK-33 antagonizes apomorphine-induced growth hormone secretion and increases basal prolactin levels in man. Neuropeptides. 4:1984;281-291
24. Okubo T., Harada S. Polymorphisms of the CCK, CCKAR and CCKBR genes: an association with alcoholism study. J Stud Alcohol. 62:2001;413-421
25. Okubo T., Harada S., Higuchi S., Matsushita S. Investigation of quantitative trait loci in the CCKAR gene with susceptibility to alcoholism. Alcohol Clin Exp Res. 26:(Suppl):2002;2S-5S
26. Peselow E., Angrist B., Sudilovsky A., Corwin J., Siekierski J., Trent F., et al. Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia. Psychopharmacology. 91:1987;80-84
27. Shergill S.S., Murray R.M., McGuire P.K. Auditory hallucinations: a review of psychological treatments. Schizophr Res. 32:1998;137-150
28. Slade P., Bentall R. Sensory Deception: A Scientific Analysis of Hallucinations. 1988;Croom Helm, London
29. Stephane M., Barton S., Boutros N.N. Auditory verbal hallucinations and dysfunction of the neural substrates of speech. Schizophr Res. 50:2001;61-78
30. Tachikawa H., Harada S., Kawanishi Y., Okubo T., Shiraishi H. Novel polymorphisms of the human cholecystokinin A receptor gene: An association analysis with schizophrenia. Am J Med Genet. 96:2000;141-145
31. Tachikawa H., Harada S., Kawanishi Y., Okubo T., Suzuki T. Linked polymorphisms (-333G > T and -286 A > G) in the promoter region of the CCK- receptor gene may be associated with schizophrenia. Psychiatry Res. 103:2001;147-155
32. Vaccarino F.J. Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviours. Neurosci Biobehav Rev. 18:1994;207-214
33. Vanakoski J., Virkkunen M., Naukkarinen H., Goldman D. No association of CCK and CCK (B) receptor polymorphisms with alcohol dependence. Psychiatry Res. 102:2001;1-7
34. Wei J., Hemmings G.P. The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia. Eur Psychiatry. 14:1999;67-70
35. Weiss A.P., Heckers S. Neuroimaging of hallucinations: a review of the literature. Psychiatry Res. 92:1999;61-74
36. Zachrisson O., de Belleroche J., Wendt K.R., Hirsch S., Lindefors N. Cholecystokinin CCK(B) receptor mRNA isoforms: expression in schizophrenic brains. Neuroreport. 10:1999;3265-3268
37. Zhang X.Y., Zhou D.F., Zhang P.Y., Wei J. The CCK-A receptor gene possibly associated with positive symptoms of schizophrenia. Mol Psychiatry. 5:2000;239-240